

Gross Cystic Disease Fluid Protein-15 (GCDFP-15)

Concentrated and Prediluted Monoclonal Antibody

Control Number: 902-113-082817

Catalog Number:	ACR 113 A, B	APR 113 AA
Description:	0.1, 0.5 ml, concentrated	6.0 ml, prediluted
Dilution:	1:50 -1:100	Ready-to-use
Diluent:	Da Vinci Green	N/A

Intended Use:

For Research Use Only. Not for use in diagnostic procedures.

Summary and Explanation:

Gross cystic disease fluid is a pathologic secretion from breast composed of several glycoproteins, including GCDFP-15. It is considered to be a marker of apocrine differentiation. Numerous studies have shown GCDFP-15 (BRST-2) to be a specific marker for breast cancer in formalin-fixed paraffin-embedded tissues and in cytologic preparation (fine needle aspirates). Studies on breast cancer have shown, with respect to specificity and sensitivity, an overall rating of 95% and 74% respectively. Another study was conducted on fine needle aspirates and statistics showed that 56.5% of primary and recurrent or metastatic breast carcinomas were expressed with GCDFP-15. Other types of tissues that express GCDFP-15 are axillary sweat glands and submandibular salivary glands.

Source: Mouse monoclonal

Species Reactivity: Human; others not tested

Clone: D6

Isotype: IgG2a

Total Protein Concentration: ~10 mg/ml. Call for lot specific Ig concentration.

Epitope/Antigen: Gross Cystic Disease Fluid Protein-15

Cellular Localization: Cytoplasmic

Positive Control: Breast Cancer

Known Applications:

Immunohistochemistry (formalin-fixed paraffin-embedded tissues)

Supplied As: Buffer with protein carrier and preservative.

Storage and Stability:

Store at 2°C to 8°C. Do not use after expiration date printed on vial. If reagents are stored under conditions other than those specified in the package insert, they must be verified by the user. Diluted reagents should be used promptly; any remaining reagent should be stored at 2°C to 8°C.

Protocol Recommendations:**Peroxide Block:**

Block for 5 minutes with Biocare's Peroxidized 1.

Pretreatment Solution (recommended): N/A

Pretreatment Protocol: N/A

Digestion Method:

Digest with Pepsin enzyme for 5 minutes at 37°C -or- for 15 minutes at RT.

Protein Block (Optional): Incubate for 10-15 minutes at RT with Biocare's Background Sniper.

Primary Antibody: Incubate for 30 minutes at RT.

Probe: Incubate for 10 minutes at RT with a probe.

Polymer: Incubate for 10 minutes at RT with a polymer.

Chromogen:

Incubate for 5 minutes at RT when using Biocare's DAB. - OR - Incubate for 10-20 minutes at RT when using Biocare's Vulcan Fast Red.

Counterstain:

Counterstain with hematoxylin. Rinse with deionized water. Apply Tacha's Bluing Solution for 1 minute. Rinse with deionized water.

Technical Note:

This antibody has been standardized with Biocare's MACH 4 detection system. It can also be used on an automated staining system and with other Biocare polymer detection kits. Use TBS buffer for washing steps.

Limitations:

This product is provided for Research Use Only (RUO) and is not for use in diagnostic procedures. Suitability for specific applications may vary and it is the responsibility of the end user to determine the appropriate application for its use.

Precautions:

1. This antibody contains less than 0.1% sodium azide. Concentrations less than 0.1% are not reportable hazardous materials according to U.S. 29 CFR 1910.1200, OSHA Hazard communication and EC Directive 91/155/EC. Sodium azide (NaN₃) used as a preservative is toxic if ingested. Sodium azide may react with lead and copper plumbing to form highly explosive metal azides. Upon disposal, flush with large volumes of water to prevent azide build-up in plumbing. (Center for Disease Control, 1976, National Institute of Occupational Safety and Health, 1976)
2. Specimens, before and after fixation, and all materials exposed to them should be handled as if capable of transmitting infection and disposed of with proper precautions. Never pipette reagents by mouth and avoid contacting the skin and mucous membranes with reagents and specimens. If reagents or specimens come in contact with sensitive areas, wash with copious amounts of water.
3. Microbial contamination of reagents may result in an increase in nonspecific staining.
4. Incubation times or temperatures other than those specified may give erroneous results. The user must validate any such change.
5. Do not use reagent after the expiration date printed on the vial.
6. The MSDS is available upon request and is located at <http://biocare.net/support/msds/>.

Technical Support:

Contact Biocare's Technical Support at 1-800-542-2002 for questions regarding this product.

Warranty:

There are no warranties, expressed or implied, which extend beyond this description. Biocare is not liable for property damage, personal injury, or economic loss caused by this product.

References:

1. Hall RE, Clements JA, Birrell SN, Tilley WD. Prostate-specific antigen and gross cystic disease fluid protein-15 are co-expressed in androgen receptor-positive breast tumours. *Br J Cancer* 1998 Aug;78(3):360-5.
2. Viacava P, Naccarato AG, Bevilacqua G. Spectrum of GCDFP-15 expression in human fetal and adult normal tissues. *Virchows Arch* 1998 Mar;432(3):255-60.
3. Fiel MI, Cernaianu G, Burstein DE, Batheja N. Value of GCDFP-15 (BRST-2) as a specific immunocytochemical marker for breast carcinoma in cytologic specimens. *Acta Cytol* 1996 Jul-Aug;40(4):637-41.
4. Wallace ML, Smoller BR. Differential sensitivity of estrogen/progesterone receptors and BRST-2 markers in metastatic ductal and lobular breast carcinoma to the skin. *Am J Dermatopathol* 1996 Jun;18(3):241-7.
5. Wick MR, Lillemoe TJ, Copland GT, Swanson PE, Manivel JC, Kiang DT. Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin *Hum Pathol* 1989 Mar;20(3):281-7.
6. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 "Decontamination of Laboratory Sink Drains to Remove Azide Salts."
7. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers from Occupationally Acquired Infections; Approved guideline-Third Edition CLSI document M29-A3 Wayne, PA 2005.